(Q36934787)

17 August 2017

1 reference

title

Targeted therapies for kidney cancer in urologic practice (English)

1 reference

17 August 2017

1 reference

Naomi B Haas

1

1 reference

17 August 2017

Robert G Uzzo

series ordinal

2

1 reference

17 August 2017

publication date

1 September 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

25

1 reference

17 August 2017

issue

5

1 reference

17 August 2017

page(s)

420-432

1 reference

17 August 2017

cites work

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Increased incidence of serendipitously discovered renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Prognostic significance of morphologic parameters in renal cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Role of molecular markers in the diagnosis and therapy of renal cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Molecular profiling and classification of sporadic renal cell carcinoma by quantitative methylation analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

The natural history of observed enhancing renal masses: meta-analysis and review of the world literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Laparoscopic partial nephrectomy: 3-year followup

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Renal cryoablation: outcome at 3 years.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

7 January 2021

Genetics of human cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Alterations in DNA Methylation: A Fundamental Aspect of Neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

von Hippel-Lindau Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

A comprehensive analysis of loss of heterozygosity caused by hemizygous deletions in renal cell carcinoma using a subtraction library

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Cytogenetic analysis of epithelial renal-cell tumors: relationship with a new histopathological classification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Collecting duct carcinoma: cytogenetic characterization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Targeted agents for the treatment of advanced renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Sunitinib in patients with metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

A mammalian protein targeted by G1-arresting rapamycin-receptor complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Mechanisms of hypertension associated with BAY 43-9006.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Cutaneous side-effects of kinase inhibitors and blocking antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Hair depigmentation during chemotherapy with a class III/V receptor tyrosine kinase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Adjuvant therapy for high-risk renal cell carcinoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Adjuvant therapy of renal cell carcinoma: patient selection and therapeutic options.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.009

10.1016/J.UROLONC.2007.05.009

7 January 2021

Identifiers

DOI

1 reference

17 August 2017

1 reference